Skip to main content

Clozapine graphicThe purpose of the North Carolina Clozapine Network (NCCN) is to increase clozapine use across North Carolina. Clozapine treatment for patients with schizophrenia has consistently demonstrated superior outcomes in several measures, including increases in quality of life and functioning, and decreases in psychiatric hospitalizations and mortality*. Despite these clear advantages clozapine remains vastly underutilized according to North Carolina Medicaid with only 1 in 6 individuals who have treatment resistant schizophrenia being prescribed this evidence-based treatment.

Clozapine underutilization is most often due to real or perceived complexities of its use. There are many barriers to clozapine use that include providers, pharmacies, pharmacists and patients. Discomfort with: clozapine initiation, maintenance, monitoring, and response to laboratory abnormalities often impede its use by providers. Negotiating REMS, restrictions on dispensing, and lack of clozapine availability are obstacles faced by many pharmacies and pharmacists. Patients often face challenges with dose titrations and tapers, finding laboratories for the required monitoring, and locating providers who prescribe clozapine. The NCCN was founded by the UNC Center for Excellence in Community Mental Health to help address these and other barriers to clozapine use.


Additional Information:

NCCN Telephone Consultation Service

NCCN Inpatient Clozapine Initiation Program

Frequently Asked Questions (Coming Soon)
– clozapine prescribing, monitoring, side effects, and pharmacy-related inquiries

Our Experts (Coming Soon)


*(McEvoy et al., Am J Psychiatry, 2006; Leucht et al., Lancet, 2011; Tiihonen, Am J Psychiatry, 2011; Tiihonen, JAMA Psychiatry, 2017)